Publications by authors named "Scott Reines"

Claim this Profile
R
ROC Analysis of Biomarker Combinations in Fragile X Syndrome-Specific Clinical Trials: Evaluating Treatment Efficacy via Exploratory Biomarkers.
Jordan E Norris, Elizabeth M Berry-Kravis, Mark D Harnett, Scott A Reines, Melody R Smith

Transl Psychiatry· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Auditory N1 event-related potential amplitude is predictive of serum concentration of BPN14770 in fragile X syndrome.
Jordan E Norris, Elizabeth M Berry-Kravis, Mark D Harnett, Scott A Reines, Melody A Reese

Mol Autism· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Auditory N1 event-related potential amplitude is predictive of serum concentration of BPN14770 in fragile x syndrome.
Jordan E Norris, Elizabeth M Berry-Kravis, Mark D Harnett, Scott A Reines, Melody A Reese

Res Sq· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial.
Elizabeth M Berry-Kravis, Mark D Harnett, Scott A Reines, Melody A Reese, Lauren E Ethridge

Nat Med· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Intravenously Administered Tramadol in Patients with Moderate to Severe Pain Following Bunionectomy: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study.
Neil K Singla, Richard Pollak, Ira Gottlieb, David Leiman, Harold Minkowitz, Scott Reines

Pain Ther· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IV tramadol: A novel option for US patients with acute pain-A review of its pharmacokinetics, abuse potential and clinical safety record.
Lucy Lu, Mark Harnett, Scott A Reines

J Opioid Manag· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravenous Tramadol is Effective in the Management of Postoperative Pain Following Abdominoplasty: A Three-Arm Randomized Placebo- and Active-Controlled Trial.
Harold Minkowitz, Hernan Salazar, David Leiman, Daneshvari Solanki, Lucy Lu, Scott Reines

Drugs R D· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Misuse of Tramadol in the United States: An Analysis of the National Survey of Drug Use and Health 2002-2017.
Scott A Reines, Bonnie Goldmann, Mark Harnett, Lucy Lu

Subst Abuse· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing the Pharmacokinetics of 2 Novel Intravenous Tramadol Dosing Regimens to Oral Tramadol: A Randomized 3-Arm Crossover Study.
Lucy Lu, Michael Ryan, Mark Harnett, George J Atiee, Scott A Reines

Clin Pharmacol Drug Dev· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IV Tramadol - A New Treatment Option for Management of Post-Operative Pain in the US: An Open-Label, Single-Arm, Safety Trial Including Various Types of Surgery.
Harold Minkowitz, David Leiman, Lucy Lu, Scott Reines, Michael Ryan

J Pain Res· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder.
William A Ball, Duane B Snavely, Richard J Hargreaves, Armin Szegedi, Christopher Lines, Scott A Reines

Hum Psychopharmacol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder.
David Michelson, Richard Hargreaves, Robert Alexander, Paulette Ceesay, Jarmo Hietala, Scott Reines

Int J Neuropsychopharmacol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is bigger better for depression trials?
Kenneth S Liu, Duane B Snavely, William A Ball, Christopher R Lines, Scott A Reines

J Psychiatr Res· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.
Martin Keller, Stuart Montgomery, William Ball, Mary Morrison, Duane Snavely, Scott Reines

Biol Psychiatry· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rofecoxib in the acute treatment of migraine: a randomized controlled clinical trial.
Joel Saper, Carl Dahlof, Yuen So, Peer Tfelt-Hansen, William Malbecq, Scott Reines

Headache· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.
Leon J Thal, Steven H Ferris, Louis Kirby, Gilbert A Block, Christopher R Lines, Scott A Reines

Neuropsychopharmacology· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Look-alike, sound-alike drug errors with Reminyl and Amaryl.
Scott A Reines

Am J Health Syst Pharm· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study.
Jan L Brandes, W Hester Visser, Mildred V Farmer, Amy L Schuhl, William Malbecq, Scott A Reines

Headache· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant.
Mats Bergström, Richard J Hargreaves, H Donald Burns, Michael R Goldberg, David Sciberras, Scott A Reines

Biol Psychiatry· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression.
Mark S Kramer, Andrew Winokur, Jeffrey Kelsey, Sheldon H Preskorn, Anthony J Rothschild, Scott A Reines

Neuropsychopharmacology· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
Paul J Hesketh, Steven M Grunberg, Richard J Gralla, David G Warr, Fausto Roila, Scott Reines

J Clin Oncol· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis